Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series

The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayan, Sooraj, Hwangbo, Kyungmin, Barkham, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757239/
https://www.ncbi.nlm.nih.gov/pubmed/35059197
http://dx.doi.org/10.1002/ccr3.5233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757239/
https://www.ncbi.nlm.nih.gov/pubmed/35059197
http://dx.doi.org/10.1002/ccr3.5233

Ejemplares similares